Volume Pricing
Research Overview
Retatrutide (LY3437943) is a first-in-class triple receptor agonist that simultaneously targets the GIP, GLP-1, and glucagon receptors. This combined mechanism distinguishes it from single- and dual-agonist incretin compounds and has made it one of the most actively studied next-generation molecules in metabolic research.
Preclinical and early research has examined retatrutide across energy-balance regulation, glucose metabolism, hepatic-lipid endpoints, and body-composition models, positioning it as a widely referenced reference compound in incretin and metabolic-pathway investigation.
Intended Use & Legal Disclaimer
This compound is strictly intended for in vitro laboratory research. It is not for use in humans or animals. Not to be used in foods, drugs, or medical diagnostics.
This product has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Usage is restricted to certified laboratories and qualified research professionals.
Terms of Sale
All sales by Codex Research are final. Buyers must be qualified professionals and assume full responsibility for safe handling and regulatory compliance. Every batch is independently verified by accredited third-party laboratories. Batch-specific Certificates of Analysis are available on our COAs page.
For Research Use Only · Not for Human Consumption






















Reviews
There are no reviews yet.